Lisa and Nicky Holdeman are ensuring a bright future of UH med students. Photo courtesy of University of Houston

University of Houston medical students and staff will receive a gift that's just what the doctor ordered.

A prestigious and longtime UH power couple has bequeathed two major gifts a major gift to the school's burgeoning College of Medicine. Dr. Nicky and Lisa Holdeman — who together boast more than 45 years at the university — have established an endowed and chair/professorship and a scholarship for medical students, the school announced.

In their will/trust the Holdemans have established, per UH:

  • The Nicky R. and Lisa K. Holdeman Endowed Professorship/Chair, which will support a clinical teaching faculty member responsible for the oversight and strategic direction of the College of Medicine's clinics, as well as enhancing the student and patient experience.
  • The Nicky R. and Lisa K. Holdeman Endowed Scholarship, which will support students in the College of Medicine, which was founded in 2020 on a social mission to improve health and health care in underserved communities in Houston and across Texas.

The Holdemans say that they were inspired by the UH College of Medicine's mission to address a significant statewide primary care physician shortage and how social determinants of health, such as income, housing, food supply and transportation, contribute to health outcomes.

"I have a true admiration for the comprehensive physician, someone comfortable addressing multiple health issues," Nicky Holdeman relays in a statement. "The physicians being trained at the University of Houston will be well prepared to manage most of the patients, with most conditions, most of the time. That's really what primary care medicine is all about."

As previously reported, UH's medical school will welcome its second class of 30 students this summer and will have 480 students at full enrollment, within the decade.

More on the duo, who have been married for 38 years: A UH biography notes that Nicky, physician and professor emeritus at the UH College of Optometry, served as associate dean for clinical education and executive director of the University Eye Institute during his 30 years at the college. He retired in 2019.

Meanwhile, Lisa joined UH in 2006 and serves as vice chancellor for the UH System and vice president for UH marketing and communications. She works directly with UH System Chancellor and UH President Renu Khator and school leadership.

"This gift is especially gratifying because it comes from two dedicated UH leaders whose professional careers have already contributed so much to our University's success," said Renu Khator. "That kind of enlightened commitment on their part sets an admirable example. I know I speak for many when I express our deep appreciation for their generous support of the College of Medicine and the important work it is undertaking in our community."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.